Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) EBIT (2016 - 2025)

Guided Therapeutics' EBIT history spans 16 years, with the latest figure at -$710000.0 for Q4 2025.

  • On a quarterly basis, EBIT fell 32.96% to -$710000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$2.4 million, a 12.47% decrease, with the full-year FY2025 number at -$2.4 million, down 12.52% from a year prior.
  • EBIT hit -$710000.0 in Q4 2025 for Guided Therapeutics, down from -$485000.0 in the prior quarter.
  • Over the last five years, EBIT for GTHP hit a ceiling of -$359000.0 in Q1 2024 and a floor of -$1.5 million in Q2 2023.
  • Historically, EBIT has averaged -$678750.0 across 5 years, with a median of -$592000.0 in 2021.
  • Biggest five-year swings in EBIT: plummeted 240.08% in 2021 and later soared 57.41% in 2024.
  • Tracing GTHP's EBIT over 5 years: stood at -$435000.0 in 2021, then crashed by 117.93% to -$948000.0 in 2022, then skyrocketed by 48.84% to -$485000.0 in 2023, then fell by 10.1% to -$534000.0 in 2024, then plummeted by 32.96% to -$710000.0 in 2025.
  • Business Quant data shows EBIT for GTHP at -$710000.0 in Q4 2025, -$485000.0 in Q3 2025, and -$763000.0 in Q2 2025.